September 2015

Join WhatsApp Channel 

Crack GPAT — Prepare for GPAT Online 
PharmaTutor
27 September 2015

Work as Manager- Clinical Research/Medical Monitor in Panacea Biotec

Panacea Biotec is a leading research based Health Management Company. We are engaged in research, development, manufacture & marketing of Vaccines, Bio-Pharmaceuticals and Pharmaceuticals (Rx & OTC) of international quality and Health Services. All Panacea Biotec plants are accredited by international agencies and they follow current Good Manufacturing Practices, as per WHO guidelines.

We offer stimulating work environment & a career that spells growth. In tune with our plans, we require young, aggressive, dynamic, high performing and result oriented professional.

Post: Manager- Clinical Research/Medical Monitor

27 September 2015
TOMATO CUISINES: A DELECTABLE REJOINDER TO THREAT OF CHRONIC AILMENTS?

{ DOWNLOAD AS PDF }

ABOUT AUTHORS:
Vikram S. Chauhan1*, Bina Rani2, Priyanka Bishnoi3, Raaz K. Maheshwari3
1Department of Botany, SBRM Govt PG College, Nagaur, Rajasthan, India
2Department of Engineering chemistry & Environmental Engineering, Poornima College of Engineering, Jaipur, India
3Department of Chemistry, SBRM Government PG College, Nagaur, Rajasthan, India
*vikkysingh2000@yahoo.com; rkmgreenchem.jaipur@gmail.com

ABSTRACT
With the advent of modern times, stress and pollution have led to major effect on rise of death toll due to chronic diseases. Such diseases are major cause of concern for the medical society. Lycopene, a carotenoid pigment found in tomatoes and its products has antioxidant properties due to the presence of numerous double bonds. Increased consumption of lycopene containing diet has been proposed to offer a protection against many types of cancers and cardio-vascular diseases. Its potential role as nutraceutical has been suggested in many studies. The present review deals with fundamental biochemistry, bio-availability and benefits of lycopene rich diet and its relation with some chronic diseases like various forms of cancers and cardiovascular diseases.

26 September 2015
Walk in for Fresher M.Pharm candidates as Associate Research Analyst in Thomson Reuters

Thomson Reuters is the leading source of intelligent information for the world's businesses and professionals, providing customers with competitive advantage. Intelligent information is a unique synthesis of human intelligence, industry expertise and innovative technology that provides decision-makers with the knowledge to act, enabling them to make better decisions faster. Through its more than 50,000 people across 93 countries, Thomson Reuters delivers this must-have insight to the financial, legal, tax and accounting, scientific, healthcare and media markets, and is powered by the world's most trusted news organization.

Post: Associate Research Analyst

26 September 2015
Walk in for Pharmacist in N.H.M. Program, District Health Society, Valsad | 7 Posts

Walk in Interview for below mention posts on contractual bases under N.H.M. Program, District Health Society, Valsad

Post: Pharmacist

U.S. Food and Drug Administration (FDA) has accepted BMS's filing and review a supplemental Biologics License Application (sBLA) for the Opdivo (nivolumab)+Yervoy (ipilimumab) regimen to include clinical data from CheckMate -067, a landmark trial in patients with previously untreated advanced melanoma. The FDA also granted Priority Review for this application with a target action date of January 23, 2016.

Bristol-Myers Squibb Company (BMS) and Moffitt Cancer Center today announced that they have entered into a collaboration agreement as part of Bristol-Myers Squibb’s Immuno-Oncology Rare Population Malignancy (I-O RPM) program in the U.S. The I-O RPM program is a multi-institutional initiative with academic-based cancer centers focused on the clinical investigation of immuno-oncology therapeutics as potential treatment options for patients with high risk, poor prognostic cancers, defined as a rare population malignancy.

  • GBR 1302, a HER2xCD3 bi-specific antibody has successfully completed the  preclinical  evaluation phase
  • Preclinically, GBR 1302 has demonstrated superiority over current antibody therapies against most HER2 positive cancers, including breast cancer
  • The phase 1 trial application for this antibody has been submitted  to  German regulatory  authorities.
  • GBR  1302  has the potential  to  be  used  in  the  treatment a  broad  array  of  cancers  in cluding breast cancer
  • If  confirmed  in  clinical  trials,  GBR  1302  could  constitute an innovative treatment for HER2 positive cancers, potentially  superior  to the currently available  monoclonal  antibody treatments

GlaxoSmithKline and Theravance, Inc. joined to file a supplemental Japanese New Drug Application (sJNDA) for Relvar® Ellipta® (fluticasone furoate “FF”/vilanterol “VI” or “FF/VI”) for the treatment of chronic obstructive   (COPD) with the Japanese regulatory authority during the first quarter of 2016. This decision follows results from an additional global phase III efficacy and safety study.

26 September 2015
Work as R&D Associate in Unilever

Every day, around the world, people reach for Unilever products. Our brands are trusted everywhere and, by listening to the people who buy them, we've grown into one of the world's most successful consumer goods companies. In fact, 150 million times a day, someone somewhere chooses a Unilever product.
Look in your fridge, or on the bathroom shelf, and you’re bound to see one of our well-known brands. We create, market and distribute the products that people choose to feed their families and keep themselves and their homes clean and fresh.

Post: R&D Associate(Job Number: 15000D8V)

Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending marketing authorisation for mepolizumab, which will be commercialised under the brand name Nucala, as an add-on treatment for severe refractory eosinophilic asthma in adult patients.